RxDoctor Payments Data

Geetha Krishnan, MD

Internal Medicine · Lakeland, FLNPI 1982639340

Payments from drug & device makers

$3,673in general payments, 2019–2025

Across 186 payments — averaging $19.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$947
  • AstraZeneca$356
  • Lilly USA, LLC$323
  • AbbVie$287
  • Bayer$281
  • Amgen$219
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,662100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,673 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$271,617
Medicare patients
478
Services billed
3,316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide193$290,923
EliquisApixaban253$285,679
MounjaroTirzepatide136$148,641
JardianceEmpagliflozin93$132,266
XareltoRivaroxaban113$114,392
RybelsusSemaglutide41$86,315
FarxigaDapagliflozin Propanediol81$76,734
JanuviaSitagliptin Phosphate54$55,785
TrulicityDulaglutide32$53,338
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$26,371
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog37$20,486
WegovySemaglutide15$19,844
Lantus SolostarInsulin Glargine,hum.Rec.Anlog118$15,150
Fluticasone-SalmeterolFluticasone Propion/Salmeterol74$13,635
Atorvastatin Calcium1,336$12,940

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$947$397,082249 claims
PfizerEliquis$157$285,679253 claims
Lilly USA, LLCMounjaro, Trulicity$323$201,979168 claims
Boehringer IngelheimJardiance$133$132,26693 claims
AstraZenecaFarxiga, Symbicort$356$81,61694 claims
MerckJanuvia$14$55,78554 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Arexvy$130$40,73770 claims
AbbVieSynthroid$287$5,92691 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Lakeland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →